Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Notes Payables: 2020-2025

Historic Notes Payables for SAB Biotherapeutics (SABS) over the last 3 years, with Mar 2025 value amounting to $138,554.

  • SAB Biotherapeutics' Notes Payables fell 83.42% to $138,554 in Q1 2025 from the same period last year, while for Mar 2025 it was $138,554, marking a year-over-year decrease of 83.42%. This contributed to the annual value of $275,849 for FY2024, which is 73.75% down from last year.
  • As of Q1 2025, SAB Biotherapeutics' Notes Payables stood at $138,554, which was down 49.77% from $275,849 recorded in Q4 2024.
  • SAB Biotherapeutics' 5-year Notes Payables high stood at $1.8 million for Q4 2021, and its period low was $25,013 during Q3 2022.
  • Over the past 3 years, SAB Biotherapeutics' median Notes Payables value was $493,061 (recorded in 2023), while the average stood at $501,819.
  • Its Notes Payables has fluctuated over the past 5 years, first soared by 2,065.45% in 2023, then tumbled by 83.42% in 2025.
  • Over the past 5 years, SAB Biotherapeutics' Notes Payables (Quarterly) stood at $1.8 million in 2021, then tumbled by 57.00% to $772,665 in 2022, then surged by 36.00% to $1.1 million in 2023, then tumbled by 73.75% to $275,849 in 2024, then tumbled by 83.42% to $138,554 in 2025.
  • Its last three reported values are $138,554 in Q1 2025, $275,849 for Q4 2024, and $615,818 during Q2 2024.